StockNews.com Upgrades ChromaDex (NASDAQ:CDXC) to Strong-Buy

ChromaDex (NASDAQ:CDXCGet Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday.

ChromaDex Stock Performance

Shares of CDXC opened at $1.52 on Wednesday. The firm has a market cap of $114.18 million, a PE ratio of -16.89 and a beta of 1.86. ChromaDex has a 52-week low of $1.25 and a 52-week high of $1.99. The business’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.46.

ChromaDex (NASDAQ:CDXCGet Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The firm had revenue of $19.50 million for the quarter, compared to analysts’ expectations of $20.61 million. ChromaDex had a negative return on equity of 23.28% and a negative net margin of 7.76%. Research analysts predict that ChromaDex will post -0.11 EPS for the current fiscal year.

Institutional Trading of ChromaDex

A number of institutional investors and hedge funds have recently modified their holdings of CDXC. Bank of America Corp DE lifted its position in shares of ChromaDex by 130.4% in the first quarter. Bank of America Corp DE now owns 16,469 shares of the company’s stock worth $25,000 after buying an additional 9,321 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in ChromaDex in the 2nd quarter worth $25,000. Squarepoint Ops LLC acquired a new stake in ChromaDex during the 1st quarter worth about $28,000. LPL Financial LLC grew its position in shares of ChromaDex by 52.9% during the 2nd quarter. LPL Financial LLC now owns 28,915 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of ChromaDex by 74.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock valued at $66,000 after acquiring an additional 16,800 shares during the period. Institutional investors own 14.99% of the company’s stock.

About ChromaDex

(Get Free Report)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

See Also

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.